5V5Z

Structure of CYP51 from the pathogen Candida albicans

Summary for 5V5Z

• Entry DOI: 10.2210/pdb5v5z/pdb
• Related: 5EQB 5JLC
• Descriptor: Lanosterol 14-alpha demethylase, PROTOPORPHYRIN IX CONTAINING FE, 2-[(2R)-butan-2-yl]-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one (3 entities in total)
• Functional Keywords: pathogen, candida albicans, cyp51, itraconazole, oxidoreductase-oxidoreducatse inhibitor complex, oxidoreductase/oxidoreducatse inhibitor
• Biological source: Candida albicans (strain SC5314 / ATCC MYA-2876) (Yeast)
• Total number of polymer chains: 1
• Total formula weight: 63170.55

Authors

Keniya, M.V.,Sabherwal, M.,Wilson, R.K.,Sagatova, A.A.,Tyndall, J.D.A.,Monk, B.C. (deposition date: 2017-03-15, release date: 2017-03-29, Last modification date: 2023-10-04)

Primary citation

Keniya, M.V.,Sabherwal, M.,Wilson, R.K.,Woods, M.A.,Sagatova, A.A.,Tyndall, J.D.A.,Monk, B.C.
Crystal Structures of Full-Length Lanosterol 14 alpha-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provide Tools for Antifungal Discovery.
Antimicrob.Agents Chemother., 62:-, 2018

PubMed Abstract: Targeting lanosterol 14α-demethylase (LDM) with azole drugs provides prophylaxis and treatments for superficial and disseminated fungal infections, but cure rates are not optimal for immunocompromised patients and individuals with comorbidities. The efficacy of azole drugs has also been reduced due to the emergence of drug-resistant fungal pathogens. We have addressed the need to improve the potency, spectrum, and specificity for azoles by expressing in functional, recombinant, hexahistidine-tagged, full-length LDM (CaLDM6×His) and LDM (CgLDM6×His) and determining their X-ray crystal structures. The crystal structures of CaLDM6×His, CgLDM6×His, and ScLDM6×His have the same fold and bind itraconazole in nearly identical conformations. The catalytic domains of the full-length LDMs have the same fold as the CaLDM6×His catalytic domain in complex with posaconazole, with minor structural differences within the ligand binding pocket. Our structures give insight into the LDM reaction mechanism and phenotypes of single-site CaLDM mutations. This study provides a practical basis for the structure-directed discovery of novel antifungals that target LDMs of fungal pathogens.

PubMed: 30126961
DOI: 10.1128/AAC.01134-18

Experimental method

X-RAY DIFFRACTION (2.9 Å)